Literature DB >> 1656103

Unrestricted replication of human cytomegalovirus in hydrocortisone-treated macrophages.

J L Lathey1, S A Spector.   

Abstract

Monocytes differentiated in the presence of phytohemagglutinin P-stimulated T cells could be infected with human cytomegalovirus AD169 and produced low levels of infectious virus. Additional treatment with therapeutic levels of hydrocortisone resulted in a 10- to 100-fold increase in infectious virus production. Hydrocortisone-treated cells demonstrated immediate-early protein kinetics similar to that observed with human fibroblasts, whereas a delay of up to 24 h was observed with untreated cells. Late protein production was barely detectable by immunostaining without hydrocortisone treatment. In treated cells, however, late protein was detected and the levels correlated with the number of cells producing infectious virus. This system provides a model for human cytomegalovirus infection of macrophages in humans.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1656103      PMCID: PMC250364     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

Review 1.  Cytomegalovirus infection in transplant patients.

Authors:  R F Betts
Journal:  Prog Med Virol       Date:  1982

2.  Modulation of interleukin 1 production by activated macrophages: in vitro action of hydrocortisone, colchicine, and cytochalasin B.

Authors:  S Stosić-Grujicić; M M Simić
Journal:  Cell Immunol       Date:  1982-05-15       Impact factor: 4.868

3.  The effects of a promoter of cell differentiation and selected hormones on human cytomegalovirus infection using an in vitro cell system.

Authors:  B A Forbes; C A Bonville; N L Dock
Journal:  J Infect Dis       Date:  1990-07       Impact factor: 5.226

4.  Localization of human cytomegalovirus in peripheral blood leukocytes by in situ hybridization.

Authors:  W M Dankner; J A McCutchan; D D Richman; K Hirata; S A Spector
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226

5.  Cytomegalovirus replicates in differentiated but not in undifferentiated human embryonal carcinoma cells.

Authors:  E Gönczöl; P W Andrews; S A Plotkin
Journal:  Science       Date:  1984-04-13       Impact factor: 47.728

6.  Monoclonal antibodies to cytomegalovirus: rapid identification of clinical isolates and preliminary use in diagnosis of cytomegalovirus pneumonia.

Authors:  L C Goldstein; J McDougall; R Hackman; J D Meyers; E D Thomas; R C Nowinski
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

7.  Cytomegalovirus infects human lymphocytes and monocytes: virus expression is restricted to immediate-early gene products.

Authors:  G P Rice; R D Schrier; M B Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  1984-10       Impact factor: 11.205

8.  Increased expression of HLA-DR antigens in hydrocortisone-treated monocytes.

Authors:  T L Gerrard; T R Cupps; C H Jurgensen; A S Fauci
Journal:  Cell Immunol       Date:  1984-04-01       Impact factor: 4.868

9.  Structure requirements and affinity of steroids to bind with receptor for induction of differentiation of cultured mouse myeloid leukemia cells.

Authors:  Y Honma; T Kasukabe; M Hozumi
Journal:  Gan       Date:  1977-08

10.  Evidence that glucocorticosteroids block expression of the human interleukin-6 gene by accessory cells.

Authors:  B Zanker; G Walz; K J Wieder; T B Strom
Journal:  Transplantation       Date:  1990-01       Impact factor: 4.939

View more
  59 in total

1.  Activation of transcription of the human cytomegalovirus early UL4 promoter by the Ets transcription factor binding element.

Authors:  J Chen; M F Stinski
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  Susceptibility of immature and mature Langerhans cell-type dendritic cells to infection and immunomodulation by human cytomegalovirus.

Authors:  Laura Hertel; Vashti G Lacaille; Herbert Strobl; Elizabeth D Mellins; Edward S Mocarski
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 3.  The pulmonary physician in critical care * Illustrative case 5: HIV associated pneumonia.

Authors:  R J Boyton; D M Mitchell; O M Kon
Journal:  Thorax       Date:  2003-08       Impact factor: 9.139

4.  Role of the proximal enhancer of the major immediate-early promoter in human cytomegalovirus replication.

Authors:  Hiroki Isomura; Tatsuya Tsurumi; Mark F Stinski
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

5.  Experimental human cytomegalovirus latency in CD14+ monocytes.

Authors:  Danna Hargett; Thomas E Shenk
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-01       Impact factor: 11.205

Review 6.  Chromatin-mediated regulation of cytomegalovirus gene expression.

Authors:  Matthew B Reeves
Journal:  Virus Res       Date:  2010-09-25       Impact factor: 3.303

7.  The intracellular localization of human cytomegalovirus DNA in peripheral blood leukocytes during active infections by high-resolution fluorescence in situ hybridization.

Authors:  H Hackstein; H Kirchner; G Jahn; G Bein
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

8.  A cis element between the TATA Box and the transcription start site of the major immediate-early promoter of human cytomegalovirus determines efficiency of viral replication.

Authors:  Hiroki Isomura; Mark F Stinski; Ayumi Kudoh; Sanae Nakayama; Takayuki Murata; Yoshitaka Sato; Satoko Iwahori; Tatsuya Tsurumi
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

9.  Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence.

Authors:  M Shane Smith; Gretchen L Bentz; J Steven Alexander; Andrew D Yurochko
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

10.  NF-kappaB-mediated activation of the chemokine CCL22 by the product of the human cytomegalovirus gene UL144 escapes regulation by viral IE86.

Authors:  Emma Poole; Elizabeth Atkins; Takashi Nakayama; Osamu Yoshie; Ian Groves; Antonio Alcami; John Sinclair
Journal:  J Virol       Date:  2008-02-20       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.